You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Managing the Heart Failure Patient with Reduced Ejection Fraction: New Perspectives and Emerging Evidence

  • Authors: Gregg Fonarow, MD (Activity Chair); Scott Solomon, MD; John Teerlink, MD; Jane Wilcox, MD, MSc
  • CME Released: 12/17/2021
  • Valid for credit through: 12/17/2022
Start Activity

  • Credits Available

    Physicians - maximum of 1.50 AMA PRA Category 1 Credit(s)™

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity was developed for clinicians who manage patients with heart failure.

The goals of this program are for clinicians to:

  1. Rapidly incorporate comprehensive disease-modifying medical therapy consistently in patients with HFrEF, and indicate the need to personalize treatment to improve clinical outcomes
  2. Recognize the mechanisms of action of traditional and emerging HF therapies as a basis for understanding emerging clinical evidence
  3. Describe patient populations in whom omecamtiv mecarbil has demonstrated greatest benefit
  4. Apply best practices for the treatment of patients with worsening HF and identify the potential role for emerging agents

Upon completion of this activity, participants will be able to:

  1. Indicate the “pillars of therapy” for heart failure with reduced ejection fraction (HFrEF) and their early benefits, and recognize patients who could potentially benefit from additional emerging HF therapies
  2. Gain insights into HF therapies that address contractile function
  3. Interpret analyses from a clinical outcomes trial with omecamtiv mecarbil in patients with HFrEF
  4. Discuss the treatment of patients with worsening HF


Disclosures

Voxmedia strives to ensure fair-balance, independence, objectivity, and scientific rigor in all directly or jointly sponsored educational activities. All prospective faculty are required to disclose to Voxmedia all financial relationships for the preceding 24 months (1) with any commercial interest producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients AND (2) with any commercial supporters prior to participating in the planning of an activity or developing content. Only after Voxmedia mitigates all financial relationships may faculty receive approval to participate, and are expected to contribute evidence-based material. Faculty are required to indicate areas of their presentation that are based on professional opinion vs. guidelines, meta-analysis. All information submitted will be peer-reviewed. The intent of this disclosure is not to prevent faculty from participating, but rather to provide learners with information on which they can make their own judgment of commercial bias. Voxmedia will disclose to learners that all relevant financial relationships have been mitigated in either written materials, visually and/or verbally. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation. Speakers must make a meaningful disclosure to the audience of their discussions of any unlabeled or investigational use(s) of drugs or devices.


Faculty

  • Gregg Fonarow, MD (Activity Chair)

    Interim Chief, UCLA Division of Cardiology
    Eliot Corday Chair of Cardiovascular Medicine and Science
    Professor of Medicine
    David Geffen School of Medicine at UCLA
    Los Angeles, California

    Disclosures

    Gregg Fonarow, MD, has disclosed the following relevant financial relationships:  
    Consulting: Abbott; Amgen; AstraZeneca; Bayer; Cytokinetics; Janssen; Medtronic; Merck; Novartis

  • Scott Solomon, MD

    The Edward D. Frohlich Distinguished Chair
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Disclosures

    Scott Solomon, MD, has disclosed the following relevant financial relationships:
    Consulting: AoBiome; Akros; Alnylam; Amgen; Arena; AstraZeneca; Bayer; Bristol Myers Squibb; Cardiac Dimensions; Cardior; Cardurion; CellProThera, Corvia; Cytokinetics; Daiichi-Sankyo; Dinaqor; Gilead; GlaxoSmithKline; Ironwood; Janssen; Merck; MyoKardia; Moderna; Novartis; Quantum Genetics; Roche; Sanofi Pasteur; Takeda; Tenaya; Theracos, Tremeau
    Received grants for clinical research from: Alnylam; Amgen; AstraZeneca; Bellerophon; Bayer; Bristol Myers Squibb; Celladon; Cytokinetics; Eidos; Gilead; GlaxoSmithKline; Ionis; Lone Star Heart; Mesoblast; MyoKardia; National Institutes of Health/National Heart, Lung, and Blood Institute; Neurotronik; Novartis; Respicardia; Sanofi Pasteur; Theracos
    Served as a member of an Executive Committee: COSMIC-HF and GALACTIC-HF

  • John Teerlink, MD

    Professor of Medicine
    University of California, San Francisco School of Medicine
    Director of Heart Failure
    San Francisco Veterans Affairs Medical Center
    San Francisco, California

    Disclosures

    John Teerlink, MD, has disclosed the following relevant financial relationships:  
    Consulting: Abbott; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Cytokinetics; Medtronic; Merck; Novartis; Servier; Verily; Windtree Therapeutics 
    Received grants for clinical research from: Abbott; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Cytokinetics; Medtronic; Novartis; Windtree Therapeutics

  • Jane Wilcox, MD, MSc

    Chief, Section of Heart Failure Treatment and Recovery
    Associate Professor of Medicine
    Northwestern University Feinberg School of Medicine
    Chicago, Illinois

    Disclosures

    Jane Wilcox, MD, MSc, has disclosed the following relevant financial relationships:
    Consulting: Abbott; Abiomed; Amgen; Novartis
    Received grants for clinical research from: American Heart Association; National Institutes of Health
    Served as a member of a Scientific Advisory Board: Abiomed; Cytokinetics

Voxmedia

  • John F. Kocsis, PhD

    President
    Hazlet, New Jersey

    Disclosures

    John F. Kocsis, PhD, has disclosed no relevant financial relationships.


Accreditation Statements

Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    For Physicians

  • Voxmedia designates this activity for a maximum of  1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact this provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 80% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Managing the Heart Failure Patient with Reduced Ejection Fraction: New Perspectives and Emerging Evidence

Authors: Gregg Fonarow, MD (Activity Chair); Scott Solomon, MD; John Teerlink, MD; Jane Wilcox, MD, MScFaculty and Disclosures

CME Released: 12/17/2021

Valid for credit through: 12/17/2022

processing....

Pre-Assessment Question

Before you begin, please answer the questions in this brief questionnaire.